UNSPSC 51282306: Flurithromycin

This classification denotes a macrolide antibiotic with the molecular formula C37H66FNO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56C9DTE69V, chemically known as erythromycin, 8-fluoro- but generally known as flurithromycin, which bears US NIH Compound Identifier 71260. European Medicines Agency schedules Flurithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07747MIG.

UNSPSC 51282306 Flurithromycin, a Commodity code, shows a profound mismatch between its pharmaceutical scope and the state and local opportunities recently posted under it. The code nominally covers a specific macrolide antibiotic, but the recent solicitations tagged to it include naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and medical first-aid supplies for fire rescue operations—none of which involve flurithromycin. State and local governments are soliciting broadly across pharmaceutical procurement, medical consumables, and emergency response supplies through competitive bidding, RFPs, and cooperative purchasing mechanisms, but no recent opportunity explicitly names flurithromycin as a line item or deliverable. The issuing bodies span a single county health department (Seminole County, Florida), a state health agency (Texas HHS Commission), a municipal fire department (City of Tampa), and a multistate cooperative purchasing alliance (Minnesota MMCAP), indicating activity across health departments, emergency services, and shared purchasing platforms.

The geographic spread of recent activity covers Florida, Texas, Minnesota, and Oregon through the MMCAP cooperative, but the code shows no identifiable flurithromycin-specific demand in recent state and local procurement. The City of Tampa's March 2026 IFB for medical and first-aid supplies (26P00145), with a $700,000 estimated contract value and a March 13, 2026 response deadline, and the Minnesota MMCAP RFP for generic pharmaceuticals and OTC products (S1070000015802), due March 26, 2026, represent the largest opportunities under this code's designation, though neither targets flurithromycin specifically. Seminole County's July 2026 IFB60459723LAS for naloxone and drug deactivation systems, due July 26, 2023, and the Texas HHS Commission's April 2026 RFI (HHS0017013) for direct-to-manufacturer prescription programs round out the recent activity. The code appears to be a misclassification artifact in state and local procurement systems rather than an active market for the named pharmaceutical.